Abbott (NYSE:ABT) and Dexcom (NSDQ:DXCM) each announced today that they are partnering with Insulet (NSDQ:PODD) to feed blood glucose monitor data into an automated insulin delivery system.
For Acton, Mass.–based Insulet, the agreements are a boost for its next-generation Omnipod Horizon automated insulin delivery system, which is presently an investigational device in the United States. The idea of an “artificial pancreas” — using continuous glucose monitor data to automate insulin delivery — has been a holy grail of sorts when it comes to diabetes treatment.
